We assessed the incidence and prevalence of hepatitis B (Hep B) in patients with or without diabetes mellitus (DM) using the UK Clinical Practice Research Datalink (CPRD). This was a retrospective, observational study of diabetic and nondiabetic cohorts aged 0-80 years using CPRD (NCT02324218). Incidence rates (IR) for each cohort were calcu- The Hep B IR, hospitalization and prevalence were higher in males in both cohorts. In conclusion, the risk of incident Hep B diagnosis in the diabetic cohort was not different from that in the nondiabetic cohort. However, prevalence of Hep B and Hep B-associated hospitalization rate was higher in the diabetic than in the nondiabetic cohort.
| INTRODUCTION

Hepatitis B virus (HBV) infection is a global public health issue with
increasing complication and mortality rates. 1 The prevalence of Hep B ranges from 5% to 10% in adults in sub-Saharan Africa and East Asia to <1% of in the population of Western Europe and North America.
2
Acute infections progress to chronic infections in 80%-90% of children infected in their first year of life, 30%-50% of children infected before the age of 6 and <5% of people infected as adults. About 20%-30% of chronically infected adults develop cirrhosis and/or liver can- 4 Although the prevalence of HBV in the UK is low, an increasing trend has been recently observed. 5 As HBV is stable for long periods of time on surfaces and is highly transmissible, 6 many Hep B outbreaks have occurred particularly in adults with diabetes who receive assisted blood glucose monitoring. 7 The Center for Disease Control and Prevention in the USA has received many reports of Hep B outbreaks in long-term care facilities, including nursing homes and assisted-living facilities since 1996.
These outbreaks prompted the Hepatitis Vaccines Work Group of the Advisory Committee on Immunization Practices (ACIP) to evaluate the risk of HBV infection among adults diagnosed with diabetes mellitus (DM).
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Several studies were carried out to understand the burden of Hep B among diabetics. Data from the National Health and Nutrition Examination Survey (NHANES) showed a higher prevalence of HBV infection among noninstitutionalized individuals diagnosed with diabetes as compared to nondiabetics. 8, 9 Data from the Emerging Infections Program (EIP) database showed that diabetes was independently associated with an increased risk for acute Hep B among adults without HBV risk behaviours. 10 The vaccination of adult diabetics (20-59 years) with Hep B vaccine was found to be costeffective. 11 Therefore, ACIP recommends that all individuals aged 19-59 should be vaccinated with Hep B vaccine "as soon as feasible after a diagnosis of diabetes". 7 To our knowledge, studies investigating the incidence and prevalence of Hep B in DM patients, rather than the general population, are scarce outside the United States. According to WHO estimates, the global prevalence of diabetes was 9% in 2014. 12 UK data published in 2013 reported a significant increase in the incidence and prevalence of type 2 DM. 5 It has been further projected that by 2030, the total number of adults with diabetes will increase to 9.5%
in England.
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This study was therefore undertaken to assess the incidence and prevalence of HBV diagnosis in DM and non-DM cohorts in the UK using the Clinical Practice Research Datalink (CPRD) database and hospitalization records in England.
| MATERIALS AND METHODS
| Data source, population and setting
Clinical Practice Research Datalink, an ongoing primary care database of anonymized medical records from general practitioners (GPs), covers over 11 million patients from more than 670 practices in the UK.
14 Primary care data from CPRD GOLD is in part available for linkage with Hospital Episode Statistics (HES) admitted patient care data for approximately 50% of subjects. 15 The validity of the diagnostic and prescription data in the CPRD for pharmacoepidemiological research has been well established. 16, 17 Additionally, data from a preliminary feasibility assessment for this study showed that the incidence rate (IR) of Hep B recorded in the CPRD is comparable to published estimates (data not shown).
Focus on the Patient Section (FPS)
• Hepatitis B virus (HBV) infection is the most common infection affecting the liver worldwide, and one-third of the global population is thought to have been infected anytime during their life. As a result of not recovering completely from the infection, chronic HBV infection is estimated to affect 240 million persons worldwide. HBV infections in adults can occur via sexual transmission, exposure to contaminated blood products or needles.
Hepatitis B (Hep B) outbreaks have occurred including in adults with diabetes through contamination of blood glucose testing devices.
• vaccine "as soon as feasible after a diagnosis of diabetes."
• Hepatitis B virus adult vaccination is recommended on a risk-based approach, with varying degrees of success and vaccination coverage in different countries.
• In this study, we evaluated the incidence and prevalence • The investigators concluded that the risk of Hep B new diagnosis in diabetic patients is similar to the one in nondiabetic ones. However, the prevalence of Hep B and hospitalization associated with it is higher in the diabetic group than that the nondiabetic one. The strengths, limitations and potential methodological biases of the study are discussed. 
| Study population and cohorts
Subjects were included in and could only contribute to either one of the two cohorts: DM and non-DM.
The DM cohort included subjects diagnosed with type 1 or type 2 DM, as confirmed by diagnosis READ codes (Table S1 ), reporting at least one DM diagnosis code during the study period, with or without a prescription for an antidiabetic drug. Ethnicity (established by post hoc analysis, Table 1 ) from HES records was considered first, and if it was missing or unknown, then the ethnicity recorded during the GP visit was considered.
To estimate the prevalence of Hep B diagnosis among DM patients, the DM cohort was extended to include prevalent DM patients.
DM type (1, 2 or unspecified) was based on an existing classification. 
| Outcome definition
The primary study outcome was the occurrence of incident Hep B diagnosis after inclusion in the study, that is after the DM onset date in the DM cohort. A minimum of 12 months Hep B disease-free period was required for a case to be considered incident. Hep B cases were identified as patients with at least one recorded Hep B clinical diagnosis code, hospitalization records or confirmatory diagnostic laboratory test results (Table S2 ).
The secondary analyses included new-onset or prevalent Hep B diagnosis among new-onset or prevalent DM and non-DM patients regardless of the onset of Hep B in relation to the diagnosis of DM.
The rate of Hep B-associated hospitalization among DM and non-DM patients was also assessed.
| Data collection and case ascertainment
The final study database consisted of data extracted from CPRD GOLD primary care and HES inpatient hospitalization databases. All
Hep B cases identified in the DM cohort and a subset of up to 100 cases identified in the non-DM cohort were ascertained through complete database profile review by two independent reviewers. This review included all available clinical, treatment and laboratory test histories available in CPRD to assess the positive predictive value (PPV) of the case classification algorithm.
For the calculation of the PPV, a true-positive (TP) and a falsepositive (FP) value were first estimated. TP was the number of cases defined using the algorithm and confirmed by inter-reviewer consensus assessment. FP was the number of cases defined using the algorithm but not confirmed by inter-reviewer consensus assessment. PPV was calculated by dividing TP by TP + FP. The PPV of the case definition algorithm and the inter-reviewer agreement were estimated. non-DM subjects (with 50 601 322 person-years) was identified. The statistical power was estimated according to the potential difference between the two cohorts, using parameters identified during the feasibility assessment. A random sample of the eligible non-DM subjects using a sampling ratio of 1:30 DM/non-DM was selected.
| Sample size
| Statistical analysis
To account for differences in DM and non-DM cohort characteristics and to minimize the potential bias on the unadjusted incidence and prevalence estimates, the primary analyses were complemented by sensitivity analysis. To maintain confidentiality and individual data anonymization, the planned statistical analyses were conducted only if at least five cases were observed for a given strata or subgroup.
| Primary analysis
The prevalence was estimated as the proportion of Hep B cases among all subjects in the cohort.
Hospitalization rates were estimated for the subset of subjects in each cohort eligible for HES inpatient data linkage, as authorized by their GP practices. The incidence of hospitalization was estimated similarly to the IR in the primary analyses and was based on new-onset Hep B cases in the study follow-up period recorded in the HES inpatient discharge data recorded using ICD-10 diagnosis codes.
| Sensitivity analysis
• Inclusion of HES inpatient cases: A sensitivity analysis was performed to evaluate the impact on IR estimates of including additional Hep B cases captured in the HES database but not recorded in CPRD.
• • Matched DM with non-DM analyses: A ratio of up to 10 matched non-DM subjects per DM subject was used to match the DM to non-DM subjects according to GP practice geographic area, age group at index date, gender and CPRD eligibility/follow-up period overlap. Unadjusted IRR was calculated comparing the two matched cohorts.
All statistical analyses were performed using the Statistical Analysis Systems (SAS) version 9.2 (SAS Institute Inc., Cary, North Carolina, USA).
| RESULTS
| Study population
From a total of 7 712 043 study eligible subjects, the DM cohort included 160 760 patients. From the eligible 7 551 283 subjects, the non-DM cohort included a random sample of 4 679 010 subjects ( Figure 1 ). The mean ages were 54.4 and 32.0 years, 57.20% and 50.14% were male, and ethnicity data were available for 62% and 50%
of subjects in the DM and non-DM cohorts, respectively ( Table 3 ). Of the subjects with available ethnicity information, a higher proportion of Asian ethnics was observed among Hep B incident cases in the DM cohort (20.6% vs 2.2% among DM subjects without incident Hep B) and in the non-DM cohort (8.9% vs 2.0% among non-DM subjects without incident Hep B).
| Hep B prevalence
The prevalence of Hep B ranged between 0.01% and 0.26% across the different age groups in the DM cohort and between 0% and 0.03% in the non-DM cohort (Table 4) N, number of subjects with available data; n, number of hepatitis B cases in each category; #, denotes 1-4 cases, results not disclosed; IR, incidence rate; 95% CI, 95% confidence interval; PY, person-years; DM, diabetes mellitus; NOS, not otherwise specified; y, years.
| Rate of hospitalization due to Hep B
| DISCUSSION
T A B L E 3 Incidence rate of hepatitis B by age at inclusion, gender and DM type in DM and selected at random non-DM subjects among DM and non-DM populations in the UK using the CPRD data source. Studies from the United States have reported an increased risk for HBV among persons with diabetes regardless of HBV risk behaviours. 7, 8, 10 HBV transmission among diabetics, especially in older populations, has resulted from lapses in infection control associated with blood glucose monitoring. 18 Another study showed that patients with diabetes were involved in HBV outbreaks as a consequence of the habit of performing capillary blood sampling using nondisposable multipatient devices. 19 Furthermore, an increased risk of HBV exposure has been reported in the United States. In the present study, the risk for new-onset incident Hep B among patients with DM was not different from that in non-DM subjects after adjustment for age at inclusion, gender, geographical region of the GP, year of the inclusion in the cohort and number of consultations during the 12 months prior to inclusion. The IR of Hep B in the DM cohort was highest in the 0-20 years age group. Available literature on laboratory confirmed Hep B has shown that overall the incidence of Hep B in the UK is low. 24, 25 In an earlier study conducted in the UK, the IR of Hep B among population ≥15 years of age was reported to be 1.6 per 100 000 person-year. 26 However, the authors did not consider diabetes as a risk factor for Hep B infection. The IRR estimate was not The observed prevalence of Hep B during the follow-up period was higher in the DM cohort compared to the non-DM cohort in all age groups. Males had a higher prevalence of Hep B than females in both study cohorts. These findings are in line with previous studies where a higher HBV-diabetes prevalence ratio was observed for men. 8, 26 Likewise, a study conducted in Turkey revealed higher prevalence of occult HBV infections in diabetic patients. 31 The range of prevalence observed in this study is consistent with published prevalence estimates (HPE data: 0.1% and 0.5% of the UK population).
32,33
A higher Hep B-associated hospitalization IR was observed in the DM than that in the non-DM cohort in this study.
A similar study in the United States reported a higher prevalence of Hep B among adults with DM than in those without DM. 18 Another study reported a 1.6-times (95% CI 1.3-1.9) higher prevalence of HBV infection among diabetics than nondiabetics. 8 Differences in the data reported in our study and in the US studies can be attributed to differences in the study designs. NHANES: National health and nutrition examination survey is a program of studies designed to assess the health and nutritional status of adults and children in the United States and includes a representative sample of the noninstitutionalized US population. The survey is unique in that it combines interviews and physical examinations data; therefore, Hep B is laboratory confirmed. The Emerging Infectious program is a national resource for surveillance, prevention and control of emerging infectious diseases used to study specific infectious diseases and, similarly to NHANES, includes laboratory confirmed Hep B cases while in the CPRD laboratory confirmation of Hep B is not routinely reported. 8, 10 The main strength of this study lies in the use of the CPRD database, a large population-based electronic medical record data set which can link primary and hospital data and provide a good representation of the UK population registered with a GP practice. records. However, we assumed that this was an unlikely differential between DM and non-DM subjects, unless DM subjects were subject to more intensive screening or testing than non-DM patients. HES inpatient subset data linked to CPRD were limited to England; therefore, outcomes involving hospital data were restricted to the English CPRD practices subset.
Hepatitis B vaccination coverage in the UK is very low, as until recently it was only recommended to those UK populations which are at increased risk of infection. As of 2017, Hep B vaccination will be introduced in the infant vaccination schedules through a combination vaccine. 34 There is no recommendation for Hep B vaccination of DM patients. The likelihood of Hep B vaccination was assumed to be similarly distributed between DM and non-DM patients and was therefore not considered in the analyses.
In conclusion, we found that the risk of new Hep B diagnosis after DM onset was no different to the risk among patients without DM. However, prevalence of Hep B during the follow-up period was higher in subjects who developed DM in all age groups compared to those subjects without DM. The Hep B-associated hospitalization rate was also higher in the DM cohort than in the non-DM cohort.
